Advertisement

Topics

AstraZeneca disappoints with Q1 sales but ‘remains on track’ to hit full-year growth guidance

04:12 EDT 18 May 2018 | Proactive Investors

The FTSE 100 drugs giant expects product sales, which have been in decline for a while now, to return to growth this year

Original Article: AstraZeneca disappoints with Q1 sales but ‘remains on track’ to hit full-year growth guidance

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca disappoints with Q1 sales but ‘remains on track’ to hit full-year growth guidance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...